Astrazeneca

FromAstraZeneca ([email protected])
Subject (49)Enhertu granted BTD for post-neoadjuvant early BC
Preheader (138)Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
Typography
Arial
Colors
Text Analysis
Body Words136
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekMonday
TimeAfternoon

Enhertu granted BTD for post-neoadjuvant early BC

Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
Enhertu granted BTD for post-neoadjuvant early BC